AVXL - CIK 0001314052
The table below shows ANAVEX LIFE SCIENCES CORP.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q4 2025 | Q4 2024 | Q4 2023 | Q4 2022 | Q4 2021 | Q4 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.15M | -$12.12M | -$7.32M | -$5.79M | -$3.50M | -$7.87M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | - | - | - | - | - |
| Dividends paid | - | - | - | - | - | - |
ANAVEX LIFE SCIENCES CORP. reported operating cash flow of -$39.04M for fiscal year 2025. That is down 26.7% from -$30.81M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$9.24M (FY 2016) to -$39.04M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $36.32M | $708.00K | $59.00K | $258.00K | $2.54M | $25.98M |